Disclosed are a strain for producing nattokinase and a production method therefor. In particular, the present invention involves a novel strain capable of producing nattokinase, i.e. Bacillus subtilis natto ST-1086, deposited at the China General Microbiological Culture Collection Center under CGMCC No. 17895. The present invention further involves a method for producing a nattokinase product by means of using the novel strain CGMCC No. 17895 of the present application, wherein the resulting nattokinase product can be used as a drug for dissolving thrombi. The present invention further involves the use of the nattokinase product of the present application for preparing a composition for dissolving thrombi and in a method for treating thrombi.

The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.

A method for efficiently producing PHA comprising: inoculating PHA fermentation strains into a fermentation medium for fermentation under the condition of being capable of producing PHA through fermentation; subjecting the fermentation broth to a solid-liquid separation to obtain fermentation supernatant and thallus precipitate; breaking the cell walls of the thallus precipitate, and subjecting the wall-broken products to a plate and frame filtration to prepare PHA; pre-coating a filter cloth for the plate and frame filtration with a PHA layer; at least part of the water of the fermentation medium is PHA process wastewater. The method utilizes the PHA process wastewater as at least part of the water of the fermentation medium, and filters and separates the broken thallus with the plate and frame filtration equipment pre-coated with PHA layer to prepare PHA, thereby recycling the high-salt wastewater, reducing costs, and potentially separating PHA on a large scale for industrial production.

Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

Methods for obtaining an aqueous extract of a microalgae Dunaliella salina cultivated in the absence of light in a culture medium of a yeast extract, sugar and salt include solubilising a yeast extract in water then adding sugar and salt. After solubilisation of the salt and at a pH between 5 and 8, the microalgae Dunaliella salina is added with stirring, in darkness and at room temperature, for a fermentation period of at least 12 hours. After the fermentation period, grinding and filtering are performed to separate a soluble aqueous raw extract to which salt is added. This extract undergoes sterilising filtration with a porosity threshold of less than or equal to 0.2 μm and has a pH between 3.5 and 4.5. The extract obtained by the method, compositions incorporating the extract, and methods of skincare, scalp care and skin appendage care using such compositions are also disclosed.

Disclosed is a method for evaluating if there are genomic abnormalities in cells being tested, the cells being tested being pluripotent stem cells cultivated in a culture medium or cells resulting from the induced differentiation of pluripotent stem cells, the method including a step of measuring the amount of an indicator present in the culture supernatant of the test cells, and a step of evaluating, on the basis of the amount of the indicator present, if there are genomic abnormalities in the test cells, wherein the indicator is at least one selected from the group consisting of deoxycytidine, kynurenine, putrescine, alanine, cysteine, cystathionine, and threonic acid, and whether or not there are genomic abnormalities in the test cells is evaluated on the basis of the amount of the at least one indicator present.

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.